$MNTR
Mentor Capital, Inc. Stock $mntr

$mntr Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224044898 Filed on November 13, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$154.3K
YoY Change		-82.22%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$269.00
YoY Change		-98.6%
% of Gross Profit
Operating Expenses		$154.3K
YoY Change		-82.22%
Operating Profit		-$154.3K
YoY Change		-19.95%
Interest Expense		-$2.940K
YoY Change		-109.95%
% of Operating Profit
Other Income/Expense, Net		-$2.936K
YoY Change		-82.59%
Pretax Income		-$157.2K
YoY Change		-24.99%
Income Tax
% Of Pretax Income
Net Earnings		-$157.2K
YoY Change		-9.21%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.01
Diluted Earnings Per Share		-$0.01
COMMON SHARES
Basic Shares Outstanding	21.83M shares	23.28M shares
Diluted Shares Outstanding		22.92M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$2.310M
YoY Change		385.0%
Cash & Equivalents		$1.683M
Short-Term Investments		$627.4K
Other Short-Term Assets		$12.29K
YoY Change		-87.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables		$1.060M
Total Short-Term Assets		$3.383M
YoY Change		155.16%
LONG-TERM ASSETS
Property, Plant & Equipment		$784.00
YoY Change		-99.57%
Goodwill		$0.00
YoY Change		-100.0%
Intangibles
YoY Change
Long-Term Investments		$104.4K
YoY Change		-70.28%
Other Assets		$104.4K
YoY Change		-97.15%
Total Long-Term Assets		$105.2K
YoY Change		-97.26%
TOTAL ASSETS
Total Short-Term Assets		$3.383M
Total Long-Term Assets		$105.2K
Total Assets		$3.488M
YoY Change		-32.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$6.483K
YoY Change		-87.44%
Accrued Expenses		$59.47K
YoY Change		-90.13%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$65.96K
YoY Change		-94.49%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$466.7K
YoY Change		-67.35%
Total Long-Term Liabilities		$466.6K
YoY Change		-81.71%
TOTAL LIABILITIES
Total Short-Term Liabilities		$65.96K
Total Long-Term Liabilities		$466.6K
Total Liabilities		$532.6K
YoY Change		-85.79%
SHAREHOLDERS EQUITY
Retained Earnings		-$8.975M
YoY Change		-23.28%
Common Stock		$2.183K
YoY Change		-3.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$2.955M
YoY Change
Total Liabilities & Shareholders Equity		$3.488M
YoY Change		-32.54%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$157.2K
YoY Change		-9.21%
Depreciation, Depletion And Amortization		$269.00
YoY Change		-98.6%
Cash From Operating Activities		-$103.4K
YoY Change		-47.44%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-94.91K
YoY Change		-22.8%
NET CHANGE
Cash From Operating Activities		-103.4K
Cash From Investing Activities		0.000
Cash From Financing Activities		-94.91K
Net Change In Cash		-198.3K
YoY Change		-45.84%
FREE CASH FLOW
Cash From Operating Activities		-$103.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments		usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21830393	shares
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-133997	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15989	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-157215	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-137914	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	3207309	usd
CY2024Q3	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	94910	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001599117
CY2024Q3	us-gaap	Revenues Revenues		usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2023Q3	MNTR	Unrealized Gain Loss On Investment UnrealizedGainLossOnInvestment		usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	145054	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-154279	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-145054	usd
CY2023Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	939	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	39627	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	10729	usd
CY2024Q3	MNTR	Unrealized Gain Loss On Investment UnrealizedGainLossOnInvestment	-42563	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4529	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-419293	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-427453	usd
	us-gaap	Profit Loss ProfitLoss	-297091	usd
	us-gaap	Net Income Loss NetIncomeLoss	-351821	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-435282	usd
CY2024Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-42563	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	939	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-270133	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	715	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	39627	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	10729	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	136136	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	27563	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4529	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	13580	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1291	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2024Q3	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	MNTR	Noncontrolling Interest NoncontrollingInterest		usd
CY2023Q4	MNTR	Noncontrolling Interest NoncontrollingInterest		usd
CY2023Q3	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2024Q3	us-gaap	Gross Profit GrossProfit		usd
CY2023Q3	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
CY2024Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
	MNTR	Unrealized Gain Loss On Investment UnrealizedGainLossOnInvestment		usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax		usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax		usd
CY2024Q3	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation		usd
CY2023Q3	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation		usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation		usd
CY2024Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	MNTR	Payment Of Capital Adjustment Note Receivable Reduction PaymentOfCapitalAdjustmentNoteReceivableReduction		usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2023Q4	MNTR	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDiscontinuedOperations		usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	MNTR	Cash Paid For Interest Discontinued Operations CashPaidForInterestDiscontinuedOperations		usd
	MNTR	Cash Paid For Interest Continued Operations CashPaidForInterestContinuedOperations		usd
	MNTR	Cash Paid For Income Taxes Discontinued Operations CashPaidForIncomeTaxesDiscontinuedOperations		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
	MNTR	Right Of Use Asset Obtained In Exchange For Finance Lease Liability Discontinued Operations RightOfUseAssetObtainedInExchangeForFinanceLeaseLiabilityDiscontinuedOperations		usd
	MNTR	Right Of Use Assets Acquired Through Finance Lease Liability RightOfUseAssetsAcquiredThroughFinanceLeaseLiability		usd
	MNTR	Right Of Use Assets Acquired Through Finance Lease Liability RightOfUseAssetsAcquiredThroughFinanceLeaseLiability		usd
CY2023Q4	MNTR	Investment In Account Receivable Impairment InvestmentInAccountReceivableImpairment		usd
CY2024Q3	MNTR	Investment In Account Receivable Net InvestmentInAccountReceivableNet		usd
CY2024Q3	MNTR	Investment In Account Receivable Current InvestmentInAccountReceivableCurrent		usd
CY2023Q4	MNTR	Investment In Account Receivable Current InvestmentInAccountReceivableCurrent		usd
CY2024Q3	MNTR	Investment In Account Receivable Noncurrent InvestmentInAccountReceivableNoncurrent		usd
CY2024Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross		usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross		usd
CY2024Q3	MNTR	Property And Equipment Of Discontinued Operations PropertyAndEquipmentOfDiscontinuedOperations		usd
CY2023Q4	MNTR	Property And Equipment Of Discontinued Operations PropertyAndEquipmentOfDiscontinuedOperations		usd
CY2024Q3	MNTR	Accumulated Depreciation Of Discontinued Operations AccumulatedDepreciationOfDiscontinuedOperations		usd
CY2023Q4	MNTR	Accumulated Depreciation Of Discontinued Operations AccumulatedDepreciationOfDiscontinuedOperations		usd
CY2024Q3	us-gaap	Revenues Revenues		usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2024Q3	MNTR	Property Additions PropertyAdditions		usd
CY2023Q3	us-gaap	Revenues Revenues		usd
CY2023Q3	MNTR	Property Additions PropertyAdditions		usd
	us-gaap	Revenues Revenues		usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-157215	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-137914	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-771568	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-419293	usd
	MNTR	Property Additions PropertyAdditions		usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55323
	dei	Entity Registrant Name EntityRegistrantName	Mentor Capital, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0395098
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5964 Campus Court
	dei	Entity Address City Or Town EntityAddressCityOrTown	Plano
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75093
	dei	City Area Code CityAreaCode	760
	dei	Local Phone Number LocalPhoneNumber	788-4700
	dei	Security12g Title Security12gTitle	Common Stock
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1682845	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2431299	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	627438	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	647363	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1800	usd
CY2024Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	60000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	15000	usd
CY2024Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1000000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1000000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12289	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6508	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	3382572	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4101970	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48239	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48239	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47455	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	46648	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	784	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1591	usd
CY2023Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	238849	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	104431	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	104431	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	104431	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	343280	usd
CY2024Q3	us-gaap	Assets Assets	3487787	usd
CY2023Q4	us-gaap	Assets Assets	4446841	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6483	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3152	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59474	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91460	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	65957	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94612	usd
CY2024Q3	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	466646	usd
CY2023Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	436512	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	466646	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	436512	usd
CY2024Q3	us-gaap	Liabilities Liabilities	532603	usd
CY2023Q4	us-gaap	Liabilities Liabilities	531124	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	11	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	11	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	11	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	11	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21830393	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21830393	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24686105	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24686105	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	2183	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2469	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11927705	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12101055	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8974704	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8187807	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2955184	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3915717	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3487787	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4446841	usd
	us-gaap	Revenues Revenues	-291	usd
	us-gaap	Gross Profit GrossProfit	-291	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	154279	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	637571	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	434991	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-637571	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-435282	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-250208	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	715	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	136136	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	27563	usd
	MNTR	Unrealized Gain Loss On Investment UnrealizedGainLossOnInvestment	-19925	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	13580	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1291	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2936	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7140	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-771568	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15329	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8160	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-157215	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-137914	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-786897	usd
CY2023Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-71678	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	136145	usd
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	5783	usd
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-71678	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	130362	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-157215	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-209592	usd
	us-gaap	Profit Loss ProfitLoss	-786897	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-36429	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	54730	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-157215	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-173163	usd
	us-gaap	Net Income Loss NetIncomeLoss	-786897	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.007
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.007
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.008
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.008
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.033
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.033
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.015
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.015
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22921018	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22921018	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22749918	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22749918	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23980070	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23980070	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22864781	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22864781	shares
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-157215	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2955184	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1637987	usd
CY2023Q3	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	7271	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-209592	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1421124	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3915717	usd
	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	173636	usd
	us-gaap	Profit Loss ProfitLoss	-786897	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2955184	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1726099	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1726099	usd
	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	7884	usd
	us-gaap	Profit Loss ProfitLoss	-297091	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1421124	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1421124	usd
	us-gaap	Profit Loss ProfitLoss	-786897	usd
	us-gaap	Profit Loss ProfitLoss	-297091	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	130362	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	807	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1092	usd
	MNTR	Amortization Of Discount On Investment In Account Receivable AmortizationOfDiscountOnInvestmentInAccountReceivable	-9559	usd
	MNTR	Amortization Of Discount On Investment In Account Receivable AmortizationOfDiscountOnInvestmentInAccountReceivable	-27091	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-19925	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	715	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-250208	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	900	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	45000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5781	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2629	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	3331	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	5568	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-31986	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	25715	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	30134	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	19205	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-574818	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-407208	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	14899	usd
	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	54809	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2291	usd
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	117900	usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	155519	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	50545	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	63121	usd
	MNTR	Payment Of Capital Adjustment Note Receivable Reduction PaymentOfCapitalAdjustmentNoteReceivableReduction	286	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	173350	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7884	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-173636	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	105782	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Continuing Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectContinuingOperations	-748454	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Continuing Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectContinuingOperations	-145907	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	365506	usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-137870	usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-400929	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-748454	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-319200	usd
CY2023Q4	MNTR	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Continued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuedOperations	2431299	usd
CY2022Q4	MNTR	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Continued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuedOperations	283431	usd
CY2022Q4	MNTR	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDiscontinuedOperations	506499	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2431299	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	789930	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1682845	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	137524	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	333207	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1682845	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	470731	usd
	us-gaap	Interest Paid Net InterestPaidNet	32425	usd
	MNTR	Cash Paid For Interest Discontinued Operations CashPaidForInterestDiscontinuedOperations	-16412	usd
	MNTR	Cash Paid For Interest Continued Operations CashPaidForInterestContinuedOperations	-48837	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	14289	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	11224	usd
	MNTR	Cash Paid For Income Taxes Discontinued Operations CashPaidForIncomeTaxesDiscontinuedOperations	-5784	usd
	MNTR	Cash Paid For Income Taxes Continued Operations CashPaidForIncomeTaxesContinuedOperations	14289	usd
	MNTR	Cash Paid For Income Taxes Continued Operations CashPaidForIncomeTaxesContinuedOperations	5440	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	934905	usd
	MNTR	Right Of Use Asset Obtained In Exchange For Finance Lease Liability Discontinued Operations RightOfUseAssetObtainedInExchangeForFinanceLeaseLiabilityDiscontinuedOperations	-934905	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_800_eus-gaap--NatureOfOperations_zKjAX3YsoKf1" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_008"></span>Note 1 - <span id="xdx_829_zXZX5hvkT25h">Nature of operations</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Corporate Structure Overview</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mentor Capital, Inc. (“Mentor” or “the Company”), reincorporated under the laws of the State of <span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20240101__20240930_z6yeyvkMCcNh" title="Entity incorporation, state or country code">Delaware</span> in September 2015.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity was originally founded as an investment partnership in Silicon Valley, California, by the current CEO in 1985 and subsequently incorporated under the laws of the State of California on <span id="xdx_90F_edei--EntityIncorporationDateOfIncorporation_dd_c20240101__20240930_zSlrVCv9H8Xe" title="Entity incorporation, date of incorporation">July 29, 1994</span>. On September 12, 1996, the Company’s offering statement was qualified pursuant to Regulation A of the Securities Act, and the Company began to trade its shares publicly. On August 21, 1998, the Company filed for voluntary reorganization, and on January 11, 2000, the Company emerged from Chapter 11 reorganization. The Company relocated to San Diego, California, and contracted to provide financial assistance and investment in small businesses. On May 22, 2015, a corporation named Mentor Capital, Inc. (“Mentor Delaware”) was incorporated under the laws of the State of Delaware. A shareholder-approved merger between Mentor and Mentor Delaware was approved by the California and Delaware Secretaries of State and became effective September 24, 2015, thereby establishing Mentor as a Delaware corporation. In September 2020, Mentor relocated its corporate office from San Diego, California, to Plano, Texas.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s common stock trades publicly under the trading symbol OTCQB: MNTR.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s current target industry focus includes the classic energy sectors of oil, gas, coal, uranium, and related ventures. Additionally, the Company has residual investments in legal dispute resolution services, collecting on an annuity-like financing, and the collection of a judgment that it intends to continue to pursue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mentor’s <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--TWGLLCMember_zCCGC29oHtj" title="Equity method investment, ownership percentage">100</span>% owned subsidiaries, Mentor IP, LLC (“MCIP”), Mentor Partner I, LLC, (“Partner I”), Mentor Partner II, LLC (“Partner II”), and TWG, LLC (“TWG”), are headquartered in Plano, Texas.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MCIP held intellectual property and licensing rights related to one United States and one Canadian patent associated with vape pens. On October 24, 2023, MCIP divested its intellectual property and licensing rights related to the United States and Canadian patents. Maintenance fees and secretary of state fees were expensed when paid, and no capitalized assets related to MCIP are recognized on the consolidated financial statements at September 30, 2024 and December 31, 2023 because the divestment activity had been limited to secretary of state and registered agent fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 27, 2021, the Company and Mentor Partner I entered into a Settlement Agreement and Mutual Release with the G Farma Entities and guarantors (“G Farma Settlors”) to resolve and settle all outstanding claims on an unpaid finance lease receivable and notes receivable of balances of $<span id="xdx_901_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_c20210827__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember_za34g1U2Ul9a" title="Finance lease receivable">803,399</span> and $<span id="xdx_908_ecustom--NotesReceivableRelatedParty_iI_c20210827__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember_zPKqMW4gXk0d" title="Notes receivable">1,045,051</span>, respectively, plus accrued interest (“Settlement Agreement”). On October 12, 2021, the parties filed a Stipulation for Dismissal and Continued Jurisdiction with the Superior Court of California in the County of Marin. The Court ordered that it retain jurisdiction over the parties under Section 664.6 of the California Code of Civil Procedure to enforce the Settlement Agreement until the performance in full of its terms is met.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2022, September 2022, and October 2022, the G Farma Settlors failed to make monthly payments and failed to cure each default within 10 days’ notice from the Company pursuant to the Settlement Agreement. As a result, $<span id="xdx_907_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_iI_c20220831__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zjNcqvthQAog" title="Liability for unpaid claims"><span id="xdx_902_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zeqRURy8g0Z8" title="Liability for unpaid claims"><span id="xdx_909_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_iI_c20221031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zUDXXoEDEZC9" title="Liability for unpaid claims">2,000,000</span></span></span> was added to the amount payable by the G Farma Settlors in accordance with the terms of the Settlement Agreement. The Company and Partner I sought entry of a stipulated judgment against the G Farma Settlors for (1) $<span id="xdx_90B_eus-gaap--LossContingencyDamagesSoughtValue_c20220801__20220831__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zjqXxfXMRPba" title="Remaining amount"><span id="xdx_902_eus-gaap--LossContingencyDamagesSoughtValue_c20220901__20220930__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zkw9obw711Jg" title="Remaining amount"><span id="xdx_906_eus-gaap--LossContingencyDamagesSoughtValue_c20221001__20221031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_z2tL0Hd6ut4e" title="Remaining amount">494,450</span></span></span>, the remaining amount of the $<span id="xdx_907_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_iI_c20220831__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zUjfabNFEa3e" title="Liability for unpaid claims and claims adjustment expense, net"><span id="xdx_90E_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zZUq8AabSn9k" title="Liability for unpaid claims and claims adjustment expense, net"><span id="xdx_901_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_iI_c20221031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zOipYokz3EZa" title="Liability for unpaid claims and claims adjustment expense, net">500,000</span></span></span> settlement amount, which has not yet been paid by the G Farma Settlors plus $<span id="xdx_90D_ecustom--LiabilityForAccruedUnpaidInterest_iI_c20220831__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zzg1e1QAqzAl" title="Liability for accrued unpaid interest"><span id="xdx_902_ecustom--LiabilityForAccruedUnpaidInterest_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zWhZXYcwjkVe" title="Liability for accrued unpaid interest"><span id="xdx_903_ecustom--LiabilityForAccruedUnpaidInterest_iI_c20221031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementAndMutualReleaseMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zqoG0umSdOp6" title="Liability for accrued unpaid interest">2,000,000</span></span></span> and all accrued unpaid interest, (2) the Company’s incurred costs, and (3) attorneys’ fees paid by the Company to obtain the judgment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 11, 2023, the Court entered judgment against the G Farma Settlors and in favor of Mentor and Partner I in the amount of $<span id="xdx_907_eus-gaap--LitigationSettlementAmountAwardedFromOtherParty_c20230711__20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zxwyVifUOR14" title="Litigation settlement amount awarded from other party">2,539,597</span>, which is comprised of $<span id="xdx_90C_ecustom--LitigationSettlementDefaultAmount_c20230711__20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_z9r2xY9Ny1Q3" title="Litigation settlement default amount">2,494,450</span> in principal (calculated as the aggregate settlement amount, less payments made by the G Farma Settlors, plus the default addition) plus accrued and unpaid interest of $<span id="xdx_900_eus-gaap--LitigationSettlementInterest_c20230711__20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_z1aWoGA99cYi" title="Litigation settlement interest amount">40,219</span>, costs of $<span id="xdx_905_eus-gaap--LitigationSettlementExpense_c20230711__20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_z3haxXz3f8l7" title="Litigation settlement costs">1,643</span>, and attorneys’ fees of $<span id="xdx_900_eus-gaap--LegalFees_c20230711__20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zDSOTqfLJYi" title="Attorneys fee">3,285</span> incurred by Mentor and Mentor Partner I in connection with obtaining the judgment. The judgment also accrues post-judgment interest at the rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230711__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zDgJlJ2JfmY6" title="Debt instrument, interest rate, effective percentage">10</span>% from July 11, 2023 until such time as the judgment is paid in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1 - Nature of operations (continued)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has retained the full reserve on the unpaid notes receivable balance and collections of the unpaid lease receivable balance due to the long history of uncertain payments from G Farma and the G Farma Settlors. Payments from G Farma and G Farma Settlors will be recognized in Other Income as they are received. Recovery payments of $<span id="xdx_909_eus-gaap--OtherIncome_c20220101__20221231__dei--LegalEntityAxis__custom--GFarmaLabsLimitedMember_ztGzcvk5UJie" title="Other income">3,550</span> and $<span id="xdx_90B_eus-gaap--OtherIncome_c20210101__20211231__dei--LegalEntityAxis__custom--GFarmaLabsLimitedMember_zBagLZ23uN06" title="Other income">2,000</span> were included in other income in the consolidated financial statements for the year ended December 31, 2022 and 2021, respectively. The last recovery payment was received on October 11, 2022. The $<span id="xdx_901_eus-gaap--LitigationSettlementAmountAwardedFromOtherParty_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zIDIz8eVhtQ8" title="Litigation settlement amount awarded from other party">2,539,597</span> judgment and interest receivable of $<span id="xdx_90A_eus-gaap--LitigationSettlementInterest_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GFarmaSettlorsMember_zjd45zKFBfOh" title="Interest receivable">311,014</span> for the nine months ended September 30, 2024 is fully reserved pending the outcome of the Company’s collection process. See Notes 8 and 16.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 27, 2022, Pueblo West Organics, LLC, a Colorado limited liability company (“Pueblo West”), exercised a lease prepayment option and purchased manufacturing equipment from Partner II for $<span id="xdx_90A_eus-gaap--PaymentsToAcquireMachineryAndEquipment_pdp0_c20220927__20220927__dei--LegalEntityAxis__custom--PuebloWestOrganicsLLCMember_zmWHGAvVfSk6" title="Payment to acquire machinery and equipment">245,369</span>. On September 28, 2022, Partner II transferred full title to the equipment to Pueblo West. Originally, Mentor contributed $<span id="xdx_906_eus-gaap--PaymentsToAcquireMachineryAndEquipment_pdp0_c20220928__20220928__dei--LegalEntityAxis__custom--PuebloWestOrganicsLLCMember_zjOsocnVbxTj" title="Payment to acquire machinery and equipment">400,000</span> to Partner II to facilitate the purchase of manufacturing equipment to be leased from Partner II by Pueblo West under a Master Equipment Lease Agreement dated February 11, 2018, as amended. On March 12, 2019, Mentor agreed to use Partner II earnings of $<span id="xdx_909_eus-gaap--PaymentsToAcquireMachineryAndEquipment_c20190312__20190312__dei--LegalEntityAxis__custom--MentorPartnerIILLCMember_zikmIkxfDM5d" title="Payment to acquire machinery and equipment">61,368</span> to facilitate the purchase of additional manufacturing equipment to Pueblo West under a Second Amendment to the lease. See Note 8.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 18, 2022, following the filing of a declaratory relief action, Mentor received $<span id="xdx_902_ecustom--ContractualInterestsInLegalRecoveries_iI_c20221118__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z94IdZmLE2se" title="Contractual interests in legal recoveries">459,990</span> from Electrum Partners, LLC (“Electrum”) pursuant to a certain November 14, 2022 Settlement Agreement and Mutual Release, following the Company’s October 21, 2022 lawsuit against Electrum and the escrow agent in the County of San Mateo. The Company applied $<span id="xdx_906_ecustom--ContractualInterestsInLegalRecoveries_iI_c20221118__us-gaap--TypeOfArrangementAxis__custom--RecoveryPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_zMGwgT1dVv98" title="Contractual interests in legal recoveries">196,666</span> to a certain October 30, 2018, Recovery Purchase Agreement, and $<span id="xdx_901_ecustom--ContractualInterestsInLegalRecoveries_iI_c20221118__us-gaap--TypeOfArrangementAxis__custom--CapitalAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_z0YUwm4Mqsy8" title="Contractual interests in legal recoveries">200,000</span> to an October 31, 2018 and January 28, 2019 Capital Agreement. The Company applied the remaining $<span id="xdx_90A_ecustom--ContractualInterestsInLegalRecoveries_iI_c20221118__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_zJ5ExPuayZF4" title="Contractual interests in legal recoveries">63,324</span> to its $<span id="xdx_909_ecustom--ContractualInterestEquityInterest_iI_c20221118__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_z7iTUeyqLck4" title="Contractual interest equity interest">194,028</span> equity interest in Electrum; this resulted in a $<span id="xdx_90C_eus-gaap--LossOnSaleOfInvestments_pp0p0_c20221118__20221118__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElectrumPartnersLLCMember_zfhTB9pSgTTl" title="Loss on investment">130,704</span> loss on the Company’s investment in Electrum. See Note 9.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 22, 2017 and October 31, 2018, the Company purchased convertible notes in principal face value of $<span id="xdx_901_ecustom--ConvertibleNotesReceivable_iI_c20171122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zZ8P1NWJKup3" title="Convertible note receivable">50,000</span> and $<span id="xdx_90F_ecustom--ConvertibleNotesReceivable_iI_c20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zIUq55Rq5aIh" title="Convertible note receivable">25,000</span>, respectively, from NeuCourt, Inc. (“NeuCourt”) that each bore interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20171122__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zX69Jjuhpukj" title="Interest rate"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20181031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_z160v1HtVrwf" title="Interest rate">5</span></span>% per annum. On November 7, 2019, October 28, 2020, and January 4, 2022, the Company received <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20191107__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zWPbYjMaqev9" title="Warrants to purchase common stock">25,000</span>, <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201028__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zr6auzPoJ5ch" title="Warrants to purchase common stock">52,000</span>, and <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220104__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_z1vUXkfmEB4k" title="Warrants to purchase common stock">27,630</span> warrants covering an aggregate of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLyjXJtixRra" title="Warrants to purchase common stock">105,130</span> shares of NeuCourt common stock exercisable at $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMySw5iQbbUf" title="Aggregate common stock, shares exercise price">0.02</span> per share in exchange for the Company’s agreement to extend the maturity dates of the convertible notes. On July 15, 2022, all principal and accrued interest on the notes were converted into a Simple Agreement for Future Equity (“SAFE”). At September 30, 2024, the SAFE Purchase Amount is $<span id="xdx_906_ecustom--OutstandingAggregatePurchaseAmount_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquitySAFEMember_zERSIf4ycu71" title="Outstanding aggregate purchase amount">93,756</span>. See Note 7.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 21, 2018, Mentor paid $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20181221__20181221__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_z4Zu4RPt4JL6" title="Stock issued, value">10,000</span> to purchase <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20181221__20181221__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_zBDv3csUtaEd" title="Stock issued, shares">500,000</span> shares of NeuCourt common stock, representing approximately <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_c20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NeuCourtIncMember_znZsmIpKt4Q9" title="Entity issued and outstanding common stock, percentage">6.13</span>% of NeuCourt’s issued and outstanding common stock at September 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company held an interest in a facilities operations company, Waste Consolidators Inc. (“WCI”) until October 2023. The Company purchased a <span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20031001__us-gaap--BusinessAcquisitionAxis__custom--WasteConsolidatorsIncMember_z7AnvAO9cNl7" title="Outstanding shares purchased percentage">50</span>% interest in WCI in 2003 and increased its ownership stake by <span id="xdx_903_ecustom--BusinessAcquisitionAdditionalPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20140114__us-gaap--BusinessAcquisitionAxis__custom--WasteConsolidatorsIncMember_zxXmhgRVSk" title="Ownership percentage">1</span>% in 2014. On October 4, 2023, the Company sold the entirety of its ownership interest in WCI for $<span id="xdx_90C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationConsideration_iI_c20231004__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--WasteConsolidatorsIncMember_zaB8rJTDGJy6" title="Disposal group, including discontinued operation, consideration">6,000,000</span>. Following the sale, the Company received no new income from WCI and had no further involvement or continuing influence over its operations. As a result of this sale, our facilities operations segment was eliminated, and its results of operations, assets, and liabilities were excluded from our continuing operations. Therefore, WCI is presented as a discontinued operation in our consolidated financial statements for the prior periods of December 31, 2023 and September 30, 2023. See Note 3.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1994-07-29
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8974704	usd
CY2022Q1	MNTR	Impairment Of Investment ImpairmentOfInvestment	116430	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	41930	usd
CY2023Q4	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	6000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zV6QB1qU5Hpf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our consolidated financial statements, and the reported amount of revenues and expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates relied upon in preparing these consolidated financial statements include revenue recognition, accounts and notes receivable reserves, expected future cash flows used to evaluate the recoverability of long-lived assets, estimated fair values of long-lived assets used to record impairment charges related to investments, goodwill, amortization periods, accrued expenses, and recoverability of the Company’s net deferred tax assets and any related valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. Acquisitions and divestitures are not announced until certain. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q1	MNTR	Impairment Of Investment ImpairmentOfInvestment	116430	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	41930	usd
CY2023Q1	us-gaap	Purchase Obligation PurchaseObligation	117000	usd
CY2023Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	117000	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	117000	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	117000	usd
	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentImpairment_zMcOWhun9Yla" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Property and equipment</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the declining balance method over the estimated useful lives of various classes of property. The estimated lives of the property and equipment are generally as follows: computer equipment, <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zqSHZDu3Zen" title="Property and equipment, useful life">3</span> years to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zRvZCdik80G8" title="Property and equipment, useful life">5</span> years; furniture and equipment, <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zieEzcR1FCLk" title="Property and equipment, useful life">7</span> years; and vehicles and trailers, <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember__srt--RangeAxis__srt--MinimumMember_z4NB5SlGa73c" title="Property and equipment, useful life">4</span> years to <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember__srt--RangeAxis__srt--MaximumMember_z0FAqVjJhrm1" title="Property and equipment, useful life">5</span> years. Depreciation on vehicles used by our discontinued operation to service its customers is included in the cost of goods sold. All other depreciation is included in selling, general, and administrative costs in the consolidated income statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures for major renewals and improvements are capitalized, while minor replacements, maintenance, and repairs, which do not extend the asset lives, are charged to operations as incurred. Upon sale or disposition, the cost and related accumulated depreciation are removed from the accounts, and any gain or loss is included in operations. The Company continually monitors events and changes in circumstances that could indicate that the carrying balances of its property and equipment may not be recoverable in accordance with the provisions of ASC 360, “<i>Property, Plant, and Equipment</i>.” When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. See Note 6.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 2 - Summary of significant accounting policies (continued)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews intangible assets subject to amortization quarterly to determine if any adverse conditions exist or if a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, or an adverse action or assessment by a regulator. If an impairment indicator exists, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), the Company will write the carrying value down to the fair value in the period identified.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Goodwill Goodwill	0	usd
CY2023Q4	us-gaap	Goodwill Goodwill	0	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4250000	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4250000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2020	MNTR	Impairment Of Investments1 ImpairmentOfInvestments1	139148	usd
CY2021	MNTR	Impairment Of Investments1 ImpairmentOfInvestments1	22718	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	41930	usd
CY2023Q1	us-gaap	Purchase Obligation PurchaseObligation	117000	usd
CY2023Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	117000	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	117000	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	117000	usd
CY2024Q3	MNTR	Investment In Account Receivable Face Value InvestmentInAccountReceivableFaceValue	287200	usd
CY2023Q4	MNTR	Investment In Account Receivable Face Value InvestmentInAccountReceivableFaceValue	285400	usd
CY2024Q3	MNTR	Investment In Account Receivable Impairment InvestmentInAccountReceivableImpairment	-250208	usd
CY2024Q3	MNTR	Investment In Account Receivable InvestmentInAccountReceivable	36992	usd
CY2023Q4	MNTR	Investment In Account Receivable InvestmentInAccountReceivable	285400	usd
CY2024Q3	MNTR	Investment In Account Receivable Unamortized Discount InvestmentInAccountReceivableUnamortizedDiscount	36992	usd
CY2023Q4	MNTR	Investment In Account Receivable Unamortized Discount InvestmentInAccountReceivableUnamortizedDiscount	46551	usd
CY2023Q4	MNTR	Investment In Account Receivable Net InvestmentInAccountReceivableNet	238849	usd
CY2023Q4	MNTR	Investment In Account Receivable Noncurrent InvestmentInAccountReceivableNoncurrent	238849	usd
CY2024Q2	MNTR	Impairments Of Accounts Receivable ImpairmentsOfAccountsReceivable	2300	usd
CY2024Q3	MNTR	Investment In Accounts Receivable Face Value InvestmentInAccountsReceivableFaceValue	100	usd
CY2024Q2	MNTR	Investment In Account Receivable Impairment InvestmentInAccountReceivableImpairment	250208	usd
CY2024Q2	MNTR	Investment In Account Receivable Impairment InvestmentInAccountReceivableImpairment	250208	usd
CY2024Q2	MNTR	Investment In Account Receivable Face Value InvestmentInAccountReceivableFaceValue	287200	usd
CY2024Q2	MNTR	Investment In Account Receivable Unamortized Discount InvestmentInAccountReceivableUnamortizedDiscount	36992	usd
CY2024Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	10484	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	9559	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	27091	usd
CY2024Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	1060000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1015000	usd
CY2024Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	33626	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	33626	usd
CY2024Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	14613	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	14613	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48239	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48239	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47455	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	46648	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	784	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1591	usd
CY2024Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	1998-08-21
CY2024Q3	MNTR	Warrant Redemption Price WarrantRedemptionPrice	0.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P13Y9M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P14Y6M
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.62
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.64
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	153000	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	180200	usd
CY2024Q3	MNTR	Warrant Redemption Price WarrantRedemptionPrice	0.10
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	300000	shares
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	44748	shares
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	300000	shares
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	44748	shares
CY2023	MNTR	Stock Retired During Period Shares StockRetiredDuringPeriodShares	300000	shares
CY2023Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	3000000	shares
CY2023Q4	MNTR	Common Shares Outstanding Percentage CommonSharesOutstandingPercentage	0.12	pure
CY2023Q4	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	200000	usd
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	2855712	shares
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2855712	shares
CY2024Q3	MNTR	Stock Repurchase Program Average Price Paid Per Share StockRepurchaseProgramAveragePricePaidPerShare	0.058	shares
CY2024Q3	srt	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	2855712	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	MNTR	Accrued Salaries And Benefits AccruedSalariesAndBenefits	47655	usd
CY2023Q4	MNTR	Accrued Salaries And Benefits AccruedSalariesAndBenefits	30517	usd
CY2024Q3	MNTR	Accrued Retirement And Other Benefits AccruedRetirementAndOtherBenefits	680644	usd
CY2023Q4	MNTR	Accrued Retirement And Other Benefits AccruedRetirementAndOtherBenefits	667648	usd
CY2024Q3	MNTR	Offset By Shareholder Advance OffsetByShareholderAdvance	-261653	usd
CY2023Q4	MNTR	Offset By Shareholder Advance OffsetByShareholderAdvance	-261653	usd
CY2024Q3	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	466646	usd
CY2023Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	436512	usd
CY2024Q3	MNTR	Incentive Fee Percentage IncentiveFeePercentage	0.01	pure
CY2024Q3	us-gaap	Capitalization Longterm Debt And Equity CapitalizationLongtermDebtAndEquity	260000	usd
CY2024Q3	MNTR	Market Capitalization Rate MarketCapitalizationRate	0.005	pure
	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	1
	us-gaap	Incentive Fee Expense IncentiveFeeExpense	0	usd
	us-gaap	Incentive Fee Expense IncentiveFeeExpense	0	usd
	us-gaap	Loss Contingency Lawsuit Filing Date1 LossContingencyLawsuitFilingDate1	2019-05-28
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-154279	usd
CY2024Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	39627	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	269	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-145054	usd
CY2023Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	10729	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4529	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	427	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-637571	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	136136	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	807	usd
CY2024Q3	us-gaap	Assets Assets	3487787	usd
	us-gaap	Revenues Revenues	-291	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-435282	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	27563	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	13580	usd
	MNTR	Property Additions PropertyAdditions	2291	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1092	usd
CY2023Q3	us-gaap	Assets Assets	1811922	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-154279	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-145054	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-637571	usd

Files In Submission

Name	View Source	Status
0001493152-24-044898-index-headers.html	Edgar Link	pending
0001493152-24-044898-index.html	Edgar Link	pending
0001493152-24-044898.txt	Edgar Link	pending
0001493152-24-044898-xbrl.zip	Edgar Link	pending
ex31.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mntr-20240930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mntr-20240930_cal.xml	Edgar Link	unprocessable
mntr-20240930_def.xml	Edgar Link	unprocessable
mntr-20240930_lab.xml	Edgar Link	unprocessable
mntr-20240930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MNTR
Mentor Capital, Inc. Stock $mntr

2024 Q4 Form 10-Q Financial Statement

#000149315224044898 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNTR Mentor Capital, Inc. Stock $mntr

2024 Q4 Form 10-Q Financial Statement

#000149315224044898 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNTR
Mentor Capital, Inc. Stock $mntr